Prediction of heart failure in HIV-infected individuals
Prediction of heart failure in HIV-infected individuals
批准号:
9348984
负责人:
David B. Hanna
金额:
$17.77万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2021-01-31
关键词:
AffectAgeAge-YearsAgingAlcohol abuseAmericanAwardCD4 Lymphocyte CountCardiacCardiovascular DiseasesCaringCessation of lifeChicagoChronic DiseaseChronologyClinicalClinical ManagementCollaborationsComorbidityComplexComputerized Medical RecordCoronary ArteriosclerosisDataData SourcesDatabasesDepositionDiabetes MellitusDrug abuseEFRACEnsureEtiologyExpenditureFailureFatty acid glycerol estersFemaleFunctional disorderFutureGeneral PopulationGeographic LocationsHIVHIV InfectionsHIV therapyHealthcareHeart DiseasesHeart failureHeterogeneityHigh PrevalenceHospitalizationHypertensionImageIncidenceIndividualInflammationInstitutionIntakeLeadLipidsMachine LearningMedical InformaticsMentorsMethodsMinorityMinority GroupsModelingPathogenesisPatientsPhenotypePopulationPremature MortalityPreventionPrognostic FactorProviderRNARecordsReportingResearchResourcesRiskRisk FactorsRoleTranslational ResearchVariantViral Load resultVulnerable PopulationsWomanWorkage relatedantiretroviral therapybaseburden of illnesscardiovascular visualizationcareercohortcoronary fibrosiscostepidemiology studyexperienceimaging studyimmune activationimprovedindexinginnovationlearning strategymenmortalityobesity riskoutcome forecastpatient populationpre-clinicalprogramssmoking prevalencesuccesstraining opportunityvirologyvirtual
中文摘要
7. 项目总结/文摘
英文摘要
7. PROJECT SUMMARY/ABSTRACT
Half of those living with HIV in the U.S. are or will soon be >50 years of age. Heart failure, which has one of
the highest disease burdens of any age-related condition nationwide, may soon become the most costly HIV-
related comorbidity in terms of premature mortality, suffering, and healthcare expenditures. Many of its known
risk factors are common to HIV-infected and uninfected individuals alike, but less is known about its
pathogenesis in the context of suppressive HIV therapy. New evidence suggests that long-term survival with
HIV is associated with greater risks for systolic and diastolic dysfunction as well as resultant heart failure with
reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Against a
background of high diabetes, hypertension, and obesity risk in minority groups affected disproportionately by
HIV, a unique set of etiologic and prognostic factors for heart failure in the context of HIV infection likely exists.
The proposed research is a set of epidemiologic studies characterizing the role of HIV infection in heart failure
incidence and survival, based on data from the largest HIV care provider in the Bronx, NY. Aim 1 will assess
the association between HIV infection and heart failure incidence, and Aim 1b will identify risk factors, including
major comorbidities, that may lead to greater mortality in optimally treated HIV-infected heart failure patients
compared with HIV-uninfected heart failure patients. Aims 2 and 3 will implement machine learning methods
within our longitudinal electronic medical record database to construct prediction models identifying HIV+
patients at greatest risk of developing HF, and to identify unique HIV-specific phenotypes of HFpEF and
HFrEF. Prediction models developed in our clinical population (90% minority, 40% female) will be validated in
a demographically complementary HIV+ cohort in Chicago (50% minority, 15% female) to evaluate the
transportability of these models across patient populations. This award will provide ample training
opportunities for the candidate to continue his progression to an independent academic research career with
specialized experience at the intersection of HIV, cardiovascular disease, and medical informatics.
Established institutional resources and a mentoring team with a proven record of success, as well as research
conducted within a geographic area with endemic levels of HIV and heart disease, provide an ideal setting to
successfully produce high quality research with major impact. The collaboration will establish a program for
large-scale translational research in HIV and heart failure by developing a shared research platform between
two major research institutions in the Bronx and Chicago.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epidemiologic Evaluation of State AIDS Drug Assistance Program Features in the US
-
批准号:8296627
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2010
-
负责人:David B. Hanna
-
依托单位:
Epidemiologic Evaluation of State AIDS Drug Assistance Program Features in the US
-
批准号:8012038
-
项目类别:
-
资助金额:$4.14万
-
财政年份:2010
-
负责人:David B. Hanna
-
依托单位:
Epidemiologic Evaluation of State AIDS Drug Assistance Program Features in the US
-
批准号:8116059
-
项目类别:
-
资助金额:$4.18万
-
财政年份:2010
-
负责人:David B. Hanna
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: